Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy

Alice Di Rocco, Antonio Cuneo, Arianna Di Rocco, Francesco Merli, Giulia De Luca, Luigi Petrucci, Michela Ansuinelli, Domenico Penna, Francesco Rotondo, Gian Matteo Rigolin, Mariateresa Giamo, Francesca Re, Alessio Farcomeni, Maurizio Martelli, Robin Foà

Research output: Contribution to journalArticlepeer-review

Abstract

Anti-CD19 chimeric antigen receptor (CAR) T cells represent the first approved third-line therapy associated with long-term remissions in patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). Eligibility criteria to identify patients who can successfully receive CAR-T are still debated. For this reason, the aim of this study was to identify factors influencing eligibility and define a realistic patient estimate. Of 1100 DLBCL patients, 137 were included. Based on the Juliet trial inclusion criteria, only 64 patients (46.7%) would be eligible. Median overall survival (OS) was 8.04 months in eligible vs 3.23 in non-eligible patients (p < 0.001). Multivariate analysis identified stage III-IV (p = 0.017) and ECOG (Formula presented.) 2 (p < 0.001) as significant independent prognostic factors for OS. Moreover, only 64/1100 (5.8%) DLBCL patients would be truly eligible for CAR-T. Our real-life data confirm that with a (Formula presented.) longer waiting time patients with advanced stage and poor ECOG are less likely to be eligible for CAR-T cell infusion.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusE-pub ahead of print - Dec 4 2020

Keywords

  • CAR-T cell eligibility
  • CAR-T cells
  • Diffuse large B-cell lymphoma
  • relapse-refractory disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy'. Together they form a unique fingerprint.

Cite this